Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

Q2 2025 Earnings Call Transcript August 6, 2025 Charles River Laboratories International, Inc. misses on earnings ...

Charles River Laboratories' annual profit forecast raise on Wednesday was clouded by investor concerns about the higher number of order cancellations from clients, sending the contract research firm's ...

Lab services company Charles River Laboratories (NYSE:CRL) reported Q2 CY2025 results beating Wall Street’s revenue ...

Delhi High Court rules cyberbullying can be as traumatic as physical assault, upholding conviction in a case involving a minor victim and morphed ...

U.S. equities rebounded strongly from tariff and geopolitical scares to deliver healthy gains in the second quarter. Read ...

University’s discovery of one of the world’s oldest fragments of the Qur’an made international headlines. But the journey did not end ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...

CJHDevCo says it was transparent, government-monitored, delivered on promises By: Jan Escosio - Reporter / @JEPOI04 INQUIRER.net / 09:02 PM July 23, 2025 Share: ...

You don’t have to carry a press pass or work as a researcher at a major university to keep an eye on government agencies.

The CRL further noted issues related to the ongoing confirmatory IGNYTE-3 study that need addressing, including contribution of components, marking a setback for the company’s melanoma treatment ...